Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer

Related Experiment Video

Updated: Oct 12, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K

Arijit Nath1, Soham Mitra2, Tanuma Mistry3

  • 1Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Bhubaneswar, Odisha, 751024, India.

Medical Oncology (Northwood, London, England)
|November 23, 2021
PubMed

Insights

Triple-negative breast cancer (TNBC) is a challenging subtype of breast cancer. This review explores TNBC

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Triple-negative breast cancer (TNBC) lacks Estrogen receptor, Progesterone receptor, and HER2/neu expression.
  • TNBC prevalence is significant in India and West Bengal, with a high rate of chemoresistance and metastasis.
  • Conventional chemotherapy efficacy decreases in advanced TNBC stages, necessitating novel treatment strategies.

Purpose of the Study:

  • To review phenotypic and molecular variations in TNBC.
  • To explore conventional and novel pathways involved in TNBC treatment.
  • To identify strategies for overcoming chemoresistance in TNBC.

Main Methods:

  • Literature review focusing on TNBC characteristics and treatment resistance mechanisms.
  • Analysis of factors contributing to chemoresistance, including heterogeneity, cancer stem cells, and signaling pathways.
  • Exploration of emerging therapeutic targets and strategies for TNBC.

Main Results:

  • TNBC exhibits significant heterogeneity and is associated with cancer stem cells (CSCs), leading to treatment resistance.
  • Multiple molecular factors, including signaling pathway deregulation and hypoxia, contribute to TNBC chemoresistance.
  • Targeted therapies and modulators of CSCs, drug efflux, and apoptotic proteins show promise for TNBC treatment.

Conclusions:

  • Understanding TNBC's molecular complexity is crucial for developing effective treatments.
  • Targeted therapies and novel strategies are essential to overcome chemoresistance and improve outcomes for TNBC patients.
  • Further research into pathways and molecular targets will enhance therapeutic efficacy for this aggressive breast cancer subtype.
Keywords:
ChemoresistanceHeterogeneityMolecular targets and therapeuticsSignaling pathwaysTNBC

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.1K